About 300 reports

FIGURE ## CAGR of ##. ##% for the forecasted year 2017 to 2023.

  • Hepatitis
  • North America
  • United States
  • World
  • Guerbet Group

ACCORDING TO THE WHO LIVER DISEASE IN AMONG THE TENTH MOST COMMON CAUSE OF THE DEATH IN INDIA AND IT IS ESTIMATED THAT IT AFFECTS ONE IN FIVE INDIAN.

  • Hepatitis
  • World
  • Forecast
  • Market Size
  • Hitachi, Ltd.

Top ## players hold majority of stake in the market ##.

  • Hepatitis
  • World
  • Market Size
  • AbbVie Inc.
  • Bristol-Myers Squibb Company

Low ## ## ## ## ## High High Low Acquisition ## ## ## ## ## High Low STRATEGY STRENGTH ## ## ## ## ## Siemens Healthcare offers rapid diagnostic products, instrument systems, and tests.

  • Hepatitis
  • World
  • Market Size
  • QIAGEN N.V.
  • Roche Group

GlobalData Karolinska Institute reported one pharmaceuticals & healthcare deal in YTD 2018.

  • Cancer
  • Hepatitis
  • Sweden
  • Karolinska Institutet Holding
  • Takeda Pharmaceutical Company Limited

A surge in the PD-## and PD-L## inhibitors market is also attributed to remarkable developments in the healthcare infrastructure and increasing healthcare awareness.

  • Hepatitis
  • China
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.

Humanwell Healthcare Group Co., Ltd.

  • Hepatitis
  • China
  • East Asia
  • Biotest AG
  • Grifols, S.A.

Hepatology, Medicine and Policy; ##(##): ## Forns X, et al. (2017).

  • Hepatitis
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Roche Group

THE OVERALL COST BURDEN OF DAA TREATMENTS TO HEALTHCARE PROVIDERS REPRESENTS ONE OF THE MAIN BARRIERS FOR REVENUE GROWTH IN THE ##MM.

  • Hepatitis
  • Market Size
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.

One of the factors that hinder the sales of PegIntron includes the delay of treatment by healthcare providers in anticipation of the approval of newer therapeutic candidates.

  • Hepatitis
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.

You can easily book an appointment with one online.

  • Hepatitis
  • World
  • Forecast
  • Eli Lilly & Co.
  • Pfizer Inc.

Global Head and EVP of Healthcare Operations and Strategy Bornadata (Bonnie) Bain, PhD is the Global Head and EVP of Healthcare Operations and Strategy.

  • Hepatitis
  • United States
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Group

Healthcare reform has been one of the key topics on the government agenda in China.

  • Hepatitis
  • China
  • Chengdu Ronsen Pharmaceutical Co., Ltd.
  • Hualan Biological Engineering Co., Ltd.
  • Ltd. Hualan Biological Engineering Co., Ltd.

Healthcare reform has been one of the key topics on the government agenda in China.

  • Hepatitis
  • China
  • Demand
  • Beijing Union Pharmaceutical Co., Ltd.
  • Sichuan Medco Pharmaceutical Stock Co., Ltd.

IT IS THE FIRST ORAL, SINGLE-TABLET DESIGNED TO TREAT HCV FROM GENOTYPE ##-## IN ADULTS.

  • Hepatitis
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • ViiV Healthcare Ltd.

Genotype ## is the most common hepatitis C virus.

  • Hepatitis
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.

Report Code: GDHC##CL Published: November 2018 Hepatocellular Carcinoma: Competitive Landscape to 2026 Healthcare TABLE OF CONTENTS ##.

  • Hepatitis
  • United States
  • Eli Lilly & Co.
  • MedImmune, LLC
  • Merck & Co., Inc.

Report Code: GDHC##CL Published: June 2018 Hepatitis C: Competitive Landscape to 2026 Healthcare TABLE OF CONTENTS ##.

  • Hepatitis
  • China
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.

ALTHOUGH IT IS A RELATIVELY SMALL SEGMENT, IT IS CONSIDERABLY DIVERSE AND INNOVATIVE, AND CONTAINS MOLECULAR TARGETS NOT SEEN IN THE MARKETED LANDSCAPE, SUCH AS CLDN##, MIR## AND EXPORTIN ##.

  • Hepatitis
  • World
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.

And in the next ## years, that estimate is expected to increase to a one to three ratio, giving rise to concerns about a number of things, including an available workforce and the impacts on the healthcare system.

  • Hepatitis
  • China
  • Chengdu Ronsen Pharmaceutical Co., Ltd.
  • Hualan Biological Engineering Co., Ltd.
  • Ltd. Hualan Biological Engineering Co., Ltd.

Zydus Cadila Healthcare Limited Vaxart, Inc.

  • Hepatitis
  • World
  • Market Size
  • Juno Therapeutics Inc.
  • Merck & Co., Inc.

IT ALSO INTERACTS WITH HIV- ## THERAPEUTICS DIDANOSINE AND ATAZANAVIR.

  • Hepatitis
  • Market Size
  • Gilead Sciences, Inc.
  • Novartis AG
  • Roche Group

For this, advanced IT systems are required to obtain genotypic and phenotypic data.

  • Hepatitis
  • World
  • bioMerieux S.A.
  • Grifols, S.A.
  • Roche Group

Healthcare spending in the country has increased to improve the infrastructure and provide insurance coverage for better healthcare access.

  • Hepatitis
  • World
  • Alere Inc.
  • DiaSorin S.p.A.
  • Roche Group

Hepatitis B Diagnostic Tests Market: Global Industry Analysis (2012 - 2016) and Opportunity Assessment (2017 - 2027) ##.

  • Hepatitis
  • In Vitro Diagnostic Reagent
  • In Vitro Diagnostics
  • Pathology
  • Forecast

No. ## Lize East## Road, Chaoyang District, Beijing, P. R.

  • Hepatitis
  • China
  • Beijing Union Pharmaceutical Co., Ltd.
  • Livzon Group
  • Sichuan Medco Pharmaceutical Stock Co., Ltd.

Drug analysis: Cyramza

8770 10000 7800

Drug analysis: Cyramza Product Profiles Cyramza : Colorectal cancer (CRC) Cyramza : Hepatocellular carcinoma (HCC) Cyramza : Bladder cancer Cyramza : Non-small cell lung cancer (NSCLC) Cyramza : Gastric cancer LIST OF FIGURES Figure ##: Cyramza for colorectal cancer – SWOT analysis Figure ##

  • Hepatitis
  • European Union
  • Japan
  • United States
  • Supply

Hepatitis Therapeutics Market Size, Share And Trend Analysis By Disease Type By Region And Segment Forecasts, 2018 - 2025 Chapter ##.

  • Hepatitis
  • Pathology
  • Therapy
  • United States
  • Forecast

Drug analysis: Stivarga Product Profiles Stivarga : Colorectal cancer (CRC) Stivarga : Hepatocellular carcinoma (HCC) LIST OF FIGURES Figure ##: Stivarga for colorectal cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of Stivarga for colorectal canc

  • Hepatitis
  • Magnetic Resonance Imaging
  • European Union
  • Japan
  • United States

Hepatitis C

4385 5000 3900

Datamonitor Healthcare therefore expects Daklinza' s sales to continue to decline, with the drug' s use in GT-## patients forecast to cease by the end of H## 2016.

  • Hepatitis
  • European Union
  • Japan
  • North America
  • United States